Heliyon (Nov 2022)

Prevalence and predictors of dyslipidemia among HAART treated and HAART naive HIV positive clients attending Debre Tabor Hospital, Debre Tabor, Ethiopia

  • Anemut Tilahun,
  • Endeshaw Chekol,
  • Awgchew Behaile Teklemaryam,
  • Melaku Mekonnen Agidew,
  • Zelalem Tilahun,
  • Fitalew Tadele Admassu,
  • Nega Dagnaw,
  • Misganaw Asmamaw Mengstie,
  • Alebachew Amsalu,
  • Enyew Fenta Mengistu,
  • Yibeltal Akelew,
  • Tadesse Asmamaw,
  • Berihun Bantie

Journal volume & issue
Vol. 8, no. 11
p. e11342

Abstract

Read online

Background: Highly active anti-retroviral therapy has been reported to be associated with a number of side effects in human immunodeficiency virus patients among which dyslipidemia isa common metabolic disorder. Methods: A Hospital based comparative cross-sectional study among 228 HIV positive patients was conducted from July to August 2020. Socio-demographic and clinical data were collected using structured questionnaires. Fasting venous blood sample was collected and analyzed for Lipid profiles. EDTA sample was analyzed for CD4+ T cell determination. Anthropometric measurement was done. Data were analyzed using SPSS version 22. Independent t-test was done. Logistic and binary regression was done. Result: A total of 228 HIV patients were enrolled in the study. Prevalence of dyslipidemia in HAART naive and HAART treated patients was 61 (53.5%) and 84 (73.7%), respectively. The prevalence of Total Cholesterol ≥200 mg/dl was 50% and 30%; High density lipoprotein cholesterol 25 kg/m2 (AOR = 1.92, 95% C.I: 1.20–4.81) were identified as determinants of dyslipidemia. Conclusion: The mean value of lipid profile was significantly higher among HAART treated as compared to those HAART naive HIV positive clients.

Keywords